Optima Life Sciences Pvt. Ltd. is pleased to announce the strategic acquisition of Cure Medicines India Pvt. Ltd., marking a significant milestone in its journey towards building a future-ready, diversified healthcare and life sciences platform.
Founded in 2003 and based in Pune, Cure Medicines India Pvt. Ltd. has built a strong reputation as a trusted pharmaceutical manufacturer, with capabilities spanning a wide range of allopathic formulations across key therapeutic segments. The company brings proven expertise in manufacturing, formulation development, and quality systems—further strengthening Optima’s expanding ecosystem.
This acquisition aligns with Optima’s long-term vision of expanding its footprint across human and animal health, strengthening backward integration, and accelerating innovation-led growth.
Strategic Rationale:
- Portfolio Expansion: Strengthening presence in pharmaceutical formulations
- Manufacturing Capability: Access to robust infrastructure and technical know-how
- Market Synergy: Unlocking new customer segments and cross-market opportunities
- Future Growth: Building an integrated platform across health, nutrition, and therapeutics
Vinay Kulkarni, Executive Chairman, Optima Life Sciences, shared:
“At Optima, we have always believed in building for the long term—with a clear focus on science, quality, and impact. The acquisition of Cure Medicines is a natural extension of that vision. What stands out to me is the strong foundation that the Cure team has created over the years. We see immense potential in combining their capabilities with Optima’s strategic direction to build a scaled, future-ready healthcare platform. This is not just about growth—it is about creating enduring value.”
Commenting on the acquisition, Ulhas Puranik, Director of Cure Medicine, said:“Over the years, we have built Cure Medicines with a strong commitment to quality, reliability, and customer trust. We are proud of what we have created. Joining hands with Optima Life Sciences gives this legacy a powerful platform for scale and future growth. I am confident that under Optima’s leadership, the company will reach new heights while staying true to its core values.”
“Our customers operate in an environment that is constantly evolving, shaped by changing healthcare needs, scientific advancements, and rising expectations around quality and innovation. At Optima, our commitment is to stay ahead of these shifts and continue delivering solutions that create meaningful value. The acquisition of Cure Medicines strengthens our ability to serve customers with a broader portfolio, enhanced capabilities, and greater agility, ensuring we remain a relevant and trusted partner for the future,” said Dr. C.V. Chandrasekaran, Sr. Vice President – Sales, Optima Life Sciences.
Dr. Arindam Chatterjee, Vice President – Strategy, Marketing & Technology, Optima Life Sciences, added:
“This acquisition is not just an expansion—it is a strategic step towards building a more integrated, innovation-driven organization. Cure Medicines brings strong manufacturing capabilities, formulation depth, and a diversified product portfolio that perfectly complements Optima’s growth ambitions. Our focus will now be on unlocking synergies across R&D, manufacturing, and market access to create differentiated value for our customers.”
Vikrant Mahajan, GM – Finance & Accounts, Optima Life Sciences, added:
“This transaction has been underpinned by a rigorous and multi-layered due diligence process spanning financials, compliance, manufacturing systems, and operational sustainability. Our focus was not just on validating current performance, but on assessing the robustness of systems and the scalability of the business. The strength and transparency we observed in Cure Medicines gives us high confidence in the long-term value creation potential of this acquisition.”
Vivek Sadhale, Co-Founder, Legalogic Consulting, who advised Optima on the transaction, said:
“This acquisition was executed through a structured and meticulous legal process, with a strong emphasis on regulatory compliance, risk mitigation, and transaction clarity. It was a pleasure partnering with the Optima team, whose strategic intent and execution discipline enabled a smooth and well-governed transaction. We believe this deal sets a strong foundation for scalable and compliant growth going forward.”
The integration will focus on scaling operations, enhancing product pipelines, and driving cross-functional synergies to deliver greater value to customers, partners, and stakeholders.This marks the beginning of a new chapter—where science, scale, and strategy converge to shape the future of healthcare.
About Optima Life Sciences Pvt. Ltd.
Optima Life Sciences Pvt. Ltd. is a rapidly growing, innovation-driven organization operating at the intersection of animal health, human health, and life sciences, focused on delivering science-led solutions across nutrition, therapeutics, and healthcare segments.
Learn more: www.optimalife.in
